BioWorld MedTech

March 27, 2013

AdreView approved for risk evaluation in HF patients

GE Healthcare (Princeton, New Jersey) reported FDA approval of a new indication for AdreView (Iobenguane I 123 Injection), a molecular imaging agent, to link nerve function in the heart to a patient's mortality risk. Read More

Johns Hopkins students develop simple, effective cooling device

Report from Europe: Miracor treats German patient with PICSO

Washington roundup: McConnell to House; vote on stand-alone device tax repeal

Agreements/contracts: PrimeraDx to co-develop diagnostics with Quest

Deals roundup: ICCNexergy in plan to acquire Applied Power

HIT roundup: TGen tests secure connection using Obsidian's Longbow tech

Financings roundup: Medgenics reports exercise of over-allotment option

Product Briefs

People in the News

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for Jan. 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 13, 2025

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

BioWorld

The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...

Proteomics study explores how protein changes influence disease

BioWorld Science

Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

BioWorld

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...